Novelna

Novelna is an early-stage biotech company developing a proprietary AI-powered proteomics platform for biomarker discovery and diagnostic test development. The company's core focus is on creating multi-cancer early detection (MCED) tests and other diagnostics aimed at asymptomatic populations, addressing a critical unmet need where effective screening is currently lacking. With a team combining expertise in medicine, proteomics, AI, and business development, Novelna is building a broad pipeline of tests while emphasizing cost reduction and scalability. The company is privately held and appears to be in a pre-revenue, pre-clinical development stage.

AI-enabled proteomics platform for the discovery and clinical validation of novel protein biomarkers. It integrates high-quality protein measurement with artificial intelligence to develop accurate, affordable blood-based and urine-based diagnostic tests for early disease detection.

Novelna operates in the highly competitive multi-cancer early detection (MCED) market, competing against established players like Grail (Illumina), Exact Sciences, and Freenome, as well as numerous other biotech startups. Differentiation will require demonstrating superior accuracy, a broader cancer signal origin, lower cost, and/or faster development timelines through its AI-proteomics platform.